Logo image
Treatment of Smith-Lemli-Opitz Syndrome and Other Sterol Disorders
Journal article   Open access

Treatment of Smith-Lemli-Opitz Syndrome and Other Sterol Disorders

Melissa D Svoboda, Jill M Christie, Yasemen Eroglu, Kurt A Freeman and Robert D Steiner
American journal of medical genetics. Part C, Seminars in medical genetics, Vol.160(4), pp.285-294
2012
DOI: 10.1002/ajmg.c.31347
PMCID: PMC3890258
PMID: 23042642
url
https://doi.org/10.1002/ajmg.c.31347View
Published (Version of record) Open Access

Abstract

Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive genetic condition with a broad phenotype that results from deficiency of the final enzyme of the cholesterol synthesis pathway. This defect causes low or low-normal plasma cholesterol levels and increased 7- and 8-dehydrocholesterol (DHC) levels. Many therapies for SLOS and other disorders of sterol metabolism have been proposed, and a few of them have been undertaken in selected patients, but robust prospective clinical trials with validated outcome measures are lacking. We review the current literature and expert opinion on treatments for SLOS and other selected sterol disorders, including dietary cholesterol therapy, statin treatment, bile acid supplementation, medical therapies, and surgical interventions, as well as directions for future therapies and treatment research.
Medical Genetics Biological and medical sciences Disorders of blood lipids. Hyperlipoproteinemia Medical sciences Metabolic diseases

Details

Metrics

Logo image